Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 Cellular Therapy for Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
NCT07137494Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zorpocabtagene autoleucel in central nervous system lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT07137494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137494.